SG2918
PreclinicalSmall molecule
SG2918 is one of 13 small molecule programs targeting Relapsed/Refractory Multiple Myeloma. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Relapsed/refractory Multiple Myeloma
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Darzalex
Johnson & JohnsonPhase 1
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
Etentamig
AbbViePhase 1
Kyprolis
VVirionyx Corporation Limited
Preclinical
Beqalzi
BBeOne Medicines
Preclinical
AZD0120
AstraZenecaPreclinical
Linvoseltamab
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SG2918. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details